This document discusses pharmaceutical suspensions. It defines a suspension as a biphasic dispersion with insoluble solid particles uniformly distributed in a liquid external phase. Suspensions are used when drugs are insoluble, to mask taste, or for controlled drug release. Key factors in suspension formulation include particle size, viscosity, sedimentation rate, and redispersion ability. Suspension characteristics can be evaluated using sedimentation tests, rheological analysis, and other methods. Common ingredients include suspending agents, wetting agents, and buffers.
Pharmaceutical dispersions, by dr. umesh kumar sharma and shyma m s
1. 1
By :
Dr. Umesh Kumar Sharma and Shyma M S
Department of Pharmaceutics,
Mar Dioscorus College of Pharmacy,
Alathara, Sreekariyam,
Thiruvananthapuram, Kerala, India
PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
2. SUSPENSION:
A pharmaceutical suspension is a biphasic coarse
dispersion in which internal phase is dispersed
uniformly through out the external phase.
2PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
3. 3
The internal phase consisting of insoluble solid
particles having a range of size (0.5 to 5 microns)
which is maintained uniformly through out the
suspending vehicle with aid of single or
combination of suspending agent.
The external phase (suspending medium) is
generally aqueous in some instance, may be an
organic or oily liquid for non oral use.
PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
4. • Suspensions are heterogeneous systems
containing two phases.
• The external phase, which is also referred to as
the continuous phase or dispersion medium, is
generally a liquid (eg.- liquid suspensions) or
semisolid (eg.- gels), and the internal or dispersed
phase is made up of particulate matter, which is
practically insoluble in the external phase.
• The most pharmaceutical suspensions consist of
an aqueous dispersion medium.
4PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
5. THE REASONS FOR THE FORMULATION
OF A PHARMACEUTICAL SUSPENSION:
• When the drug is insoluble in the delivery
vehicle.
• To mask the bitter taste of the drug.
• To increase drug stability.
• To achieve controlled / sustained drug release.
5PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
6. 1. Antacid oral suspensions.
2. Antibacterial oral suspension.
3. Dry powders for oral suspension (antibiotic).
4. Analgesic oral suspension.
5. Anthelmintic oral suspension.
6. Anticonvulsant oral suspension.
7. Antifungal oral suspension.
EXAMPLES OF SUSPENSIONS
6PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
7. In an ideal suspension formulation, insoluble particles
should be uniformly dispersed.
• However, on standing, the solid particles in
suspensions get separated from the liquid as
sediments.
• Regardless of the amount of sedimentation, a well-
formulated suspension should re-disperse uniformly in
the continuous phase, on moderate shaking, for a
sufficient period of time.
• This allows the withdrawal of the correct amount of
medication with minimal dose variation.
7PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
8. • The rate of settling can be decreased using viscosity
improving agents, and the ease of re dispersibility can
be controlled using flocculating agents.
• Products that are too viscous, however, may not be
easy to remove from the container and may be too
difficult to transfer to the site of application.
• Furthermore, the drug diffusion process is also
expected to be hindered by high viscosity.
• Suspended particles should also be small and uniform
in size to provide a smooth and elegant product that is
free from a gritty texture.
8PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
9. • The suspended particles should not settle rapidly and
sediment produced, must be easily re-suspended by the
use of moderate amount of shaking.
• It should be easy to pour yet not watery and no
grittiness.
• It should have pleasing odour, color and palatability
and good syringeability.
• It should be physically, chemically and
microbiologically stable
• Parenteral / Ophthalmic suspension should be
sterilizable.
9PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
10. • Suspension can improve chemical stability of certain
drug. Eg.- Procaine penicillin G.
• Drug in suspension exhibits higher rate of
bioavailability than other dosage forms.
Solution > Suspension > Capsule > Compressed Tablet >
Coated tablet
• Duration and onset of action can be controlled.
Eg.- Protamine Zinc-Insulin suspension.
• Suspension can mask the unpleasant/ bitter taste of
drug. Eg. - Chloramphenicol
ADVANTAGES
10PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
11. Physical stability, sedimentation and compaction can
causes problems.
It is bulky sufficient care must be taken during
handling and transport.
It is difficult to formulate.
Uniform and accurate dose can not be achieved unless
suspension are packed in unit dosage form.
DISADVANTAGES
11PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
12. CLASSIFICATION
Based on general classes
Oral suspension. Eg. - Paracetamol suspension
Externally applied suspension Eg.-Calamine lotion
Parenteral suspension. Eg.- Insulin zinc
Based on electro kinetic nature of solid particles
Flocculated suspension.
De Flocculated suspension.
12PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
13. Based on proportion of solid particles
Dilute suspensions (2 to 10% w/v solid)
concentrated suspensions (50% w/v solid)
Based on size of solid particles
Colloidal suspension (<1 micron)
Course suspension (>1 micron)
Nano suspension (10 ng)
13PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
14. THEORY OF SEDIMENTATION
SEDIMENTATION:
Sedimentation means settling of particle (or) floccules
occur under gravitational force in liquid dosage form.
14PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
15. Velocity of sedimentation expressed by Stoke’s equation -
Where, d = Diameter of particle
r = Radius of particle
vsed.= Sedimentation velocity in cm / sec
ρs = Density of disperse phase
ρo = Density of disperse media
g = Acceleration due to gravity
ηo = Viscosity of disperse medium in poise
D2(ps-p0)g
18 ηo
15PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
16. Limitation of Stoke’s Equation
Stoke's equation applies only to:
• Spherical particles in a very dilute suspension (0.5 to 2
gm per 100 ml).
• Particles which freely settle without collision.
• Particles with no physical or chemical attraction.
16PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
17. Sedimentation Parameters
Sedimentation volume (F) or height (H) for flocculated
suspensions:
Definition: Sedimentation volume is a ratio of the
ultimate volume of sediment (Vu) to the original volume
of sediment (VO) before settling.
F = V u / VO
Where,
Vu = final or ultimate volume of sediment
VO = original volume of suspension before settling.
17PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
18. F has values ranging from less than one to greater than
one.
When F < 1 Vu < Vo
When F =1 Vu = Vo
• The system is in flocculated equilibrium and show no
clear supernatant on standing.
When F > 1 Vu > Vo
• Sediment volume is greater than the original volume
due to the network of flocs formed in the suspension
and so loose and fluffy sediment.
18PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
19. Degree of flocculation (β)
It is the ratio of the sedimentation volume of the
flocculated suspension ,F , to the sedimentation volume
of the deflocculated suspension, F∞
ß = F / F∞
ß =
The minimum value of ß is 1,when flocculated
suspension sedimentation volume is equal to the
sedimentation volume of deflocculated suspension.
(Vu/Vo) flocculated)
(Vu/Vo) deflocculated)
19PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
20. 2. Brownian Movement (Drunken walk)
• Brownian movement of particle prevents
sedimentation by keeping the dispersed material in
random motion.
• Brownian movement depends on the density of
dispersed phase and the density and viscosity of the
disperse medium.
• The kinetic bombardment of the particles by the
molecules of the suspending medium will keep the
particles suspending, provided that their size is below
critical radius (r).
20PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
21. Brownian movement can be observed
• If particle size is about 2 to 5mm,
• When the density of particle & viscosity of medium
are favorable.
21PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
22. 3.Electro kinetic Properties
Electrical double layer
Zeta Potential
The zeta potential is defined as the difference in potential
between the surface of the tightly bound layer (shear
plane) and electro-neutral region of the solution.
22PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
23. • As the potential drops off rapidly at first, followed
more gradual decrease as the distance from the surface
increases.
• This is because the counter ions close to the surface acts
as a screen that reduce the electrostatic attraction
between the charged surface and those counter ions
further away from the surface.
• Zeta potential has practical application in stability of
systems containing dispersed particles.
23PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
24. • If the zeta potential is reduced below a certain value,
the attractive forces exceed the repulsive forces, and
the particles come together.
• This phenomenon is known as flocculation.
• Thus the phenomenon of flocculation and de
flocculation depends on zeta potential carried by
particles.
24PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
25. De flocculation and flocculation
Flocculated Suspensions
• In flocculated suspension, formed flocs (loose
aggregates) will cause increase in sedimentation rate
due to increase in size of sedimenting particles.
• Hence, flocculated suspensions sediment more rapidly.
• Here, the sedimentation depends not only on the size
of the flocs but also on the porosity of flocs.
25PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
27. Deflocculated suspensions
• In deflocculated suspension, individual particles are
settling.
• Rate of sedimentation is slow, which prevents
entrapping of liquid medium which makes it difficult
to re-disperse by agitation.
• This phenomenon called ‘caking’ or ‘claying’.
• In deflocculated suspension larger particles settle fast
and smaller remain in supernatant liquid so
supernatant appears cloudy.
27PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
28. • The formulation of a suspension depends on whether
the suspension is flocculated or deflocculated.
• Three approaches are commonly involved
1. Use of structured vehicle
2. Use of controlled flocculation
3. Combination of both of the methods
FORMULATION OF SUSPENSION
28PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
30. • Structured vehicles called also thickening or suspending
agents.
• They are aqueous solutions of natural and synthetic
gums.
• These are used to increase the viscosity of the
suspension.
• It is applicable only to deflocculated suspensions. Eg. -
methyl cellulose, sodium carboxy methyl cellulose,
acacia, gelatin and tragacanth.
STRUCTURED VEHICLES
30PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
31. • These structured vehicles entrapped the particle and
reduces the sedimentation of particles.
• Thus, the use of deflocculated particles in a structure
vehicle may form solid hard cake upon long storage.
• Too high viscosity is not desirable as:
a) It causes difficulty in pouring and administration.
b) It may affect drug absorption since they adsorb on
the surface of particle and suppress the dissolution rate.
• Structured vehicle is not useful for Parenteral
suspension because they may create problem in
syringeability due to high viscosity.
31PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
32. Controlled flocculation of particles is obtained by
adding flocculating agents, which are:
(1) Electrolytes
(2) Surfactants
(3) Polymers
Flocculation in structured vehicles
• Sometimes suspending agents can be added to
flocculated suspension to retard sedimentation
Ex. – Carboxymethylcellulose (CMC), ƒCarbopo l934, ƒ
Veegum and bentonite.
Controlled flocculation
32PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
33. • Wetting agents
• Flocculating agents
• Buffers and pH adjusting agents
• Osmotic agents
• Colouring agent
• Preservatives
• External liquid vehicle
INGREDIENTS IN SUSPENSIONS
33PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
34. Small scale preparation of suspensions
Step 1:
Suspensions are prepared by grinding (or) levigating the
insoluble materials in the mortar to a smooth paste with a
vehicle containing the wetting agent.
Step 2:
All soluble ingredients are dissolved in same portion of
the vehicle and added to the smooth paste to step1 to get
slurry.
Step 3:
The slurry is transformed to a graduated cylinder, the
mortar is rinsed with successive portion of the vehicle.
34PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
35. Step 4:
Decide whether the solids are
• Suspended in a structured vehicle
• Flocculated
• Flocculated and then suspended
Add the vehicle containing the suspending agent (or)
flocculating agent.
Step-5
Make up to the final volume .
The suspension is prepared.
35PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
36. • Sedimentation method
• Rheological method
• Electro kinetic method
• Micromeritic method
Evaluation of Suspensions
36PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
37. Sedimentation method :
Two parameters are studied for determination of
sedimentation.
1. Sedimentation volume,
2. Degree of flocculation.
1. Sedimentation volume:
The suspension formulation (50mL) was poured
separately into 100mL measuring cylinders and
sedimentation volume was read after1, 2, 3 and
7days, and there after at weekly intervals for 12
weeks.
37PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
38. Where,
F = Sedimentation volume,
Vu = Ultimate height of sediment and
Vo = Initial height of total suspension
F= Vu
Vo
38
• Triplicate results were obtained for each
formulation.
• Sedimentation volume was calculated according
to the equation:
PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
39. Rheological method
• It provide information about Settling behavior.
• The arrangement of the vehicle and the particle
structural features.
• Brookfield viscometer is used to study the viscosity
of the suspension.
• It is mounted on heli path stand and using T-bar
spindle.
39PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
40. • T-bar spindle is made to descend slowly into the
suspension and the dial reading on the viscometer is
then a measure of the resistance the spindle meets at
various level.
• This technique also indicates at which level of the
suspension the structure is greater owing to particle
agglomeration.
• The dial reading is plotted against the number of turns
of the spindle.
• The better suspension show a lesser rate of increase of
dial reading with spindle turns, i.e. the curve is
horizontal for long period.
40PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
41. Electro kinetic method
• Measurement of Zeta-potential using Micro
electrophoresis apparatus &Zeta Plus (Brook haven
Instruments Corporation,USA)
• It shows the stability of a disperse system.
41PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
42. Zeta potential
• The zeta potential of the formulated suspensions was
determined using a Zeta Plus (Brook haven
Instruments Corporation,USA).
• Approximately 1mL of suspension was transferred into
a plastic cuvette using a pipette and diluted with
distilled water.
The Brook haven zeta potential software was used for the
measurement. Parameters set to a temperature of 250 ˚C
and refractive index (1.33). The zeta potential of the
formulations was determined on day 0,7, 14,21 and day
28 post formulation
42PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
43. Micromeritic method :
• The stability of suspension depends on the particle
size of the dispersed phase.
• Change in the particle size with reference to time
will provide useful information regarding the
stability of a suspension.
• A change in particle size distribution and crystal
habit studied by-
Microscopy
Coulter counter method
43PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
44. DISSOLUTION STUDY OF SUSPENSION
Introduction: The drug release from suspensions is
mainly through dissolution.
• Suspensions share many physico-chemical
characteristics of tablet & capsules with respect to
the process of dissolution.
• As tablets & capsules disintegrate into powder and
form suspensions in the biological fluids.
44PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
45. Dissolution is carried as follows:
• The apparatus consists of a cylindrical 1000-ml round
bottom flask in a multiple –spindle dissolution drive
apparatus and immersed in a controlled temp bath
maintained.
Dissolution Testing Official Method (Conventional
Method): It is known as paddle method. Dissolution
profile of the 500 mg sample suspension is determined at
37°C in 900 ml of phosphate buffer (pH 7.2 ) using at 25
RPM.
45PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
46. The paddle should position to extend to exactly 2.5
cm above the flask bottom.
The suspension is to be introduced carefully into the
flask at the bottom using a 10-ml glass syringe with
an attachment 19-cm needle.
Withdraw 5 ml of dissolution medium (and replace
with an equal volume of drug –free buffer) in a 5 ml
glass syringe.
Immediately filter through a 0.2 µm membrane and
analyze.
46PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
47. Applications
• Suspension is usually applicable for drug which are
insoluble or poorly soluble. Eg.- Prednisolone
suspension.
• To prevent degradation of drug or to improve
stability of drug. Eg.- Oxy tetracycline suspension
• To mask the taste of bitter of unpleasant drug. Eg.-
Chloramphenicol palmitate suspension
47PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
48. • Suspension of drug can be formulated for topical
application. Eg.- Calamine lotion.
• Suspension can be formulated for parentral
application in order to control rate of drug absorption.
Eg.- penicillin procaine
• Vaccines as a immunizing agent are often formulated
as suspension. Eg.- Cholera vaccine
• X-ray contrast agent are also formulated as
suspension. Eg.- Barium sulphate for examination of
alimentary tract.
48PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
49. 49
Self Micro Emulsifying Drug Delivery System
PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
50. • Self Micro Emulsifying Drug Delivery system
(SMEDDS) is a new approach to improve the
solubility of poorly soluble drugs.
• It can be ideally called as an isotropic mixture.
Drugs which are lipophilic in nature can be
formulated in this lipid based drug delivery system
• SMEDDS improves solubility thereby increases
dissolution rate and bioavailability of drugs.
• Drug, oil, surfactant, solvent and co-solvent are the
components of SMEDDS.
50PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
51. It forms small droplets due to agitation. The size of
the droplet is 10-100nm.
Absorption of drug is improved by small droplets due
to its ability to increase the interfacial surface area.
In this system, the drug is dissolved in oil, solvent or
surfactant.Co-solvents are used when required.
Once it enters into the stomach it forms micro
emulsion due to mild agitation. Agitation is caused by
the digestive motility and intestine.
SMEDDS is available as different dosage forms such
as capsules, tablets, suppositories and topical
preparations.
51PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
52. ADVANTAGES OF SMEDDS
Enhances oral bioavailability.
Delivers peptides, protein.
Available in both liquid and solid dosage form.
Poorly water soluble drugs can be used.
Improve patient compliance.
The drug is protected by oil droplets.
Drugs will not be affected by presence of food.
Has reproducible drug absorption profile.
52PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
53. Limitations Of SMEDDS
Lack of in-vitro models for evaluation.
Dissolution test cannot be completely relied on,
because this formulation depends on digestion.
It causes GIT irritation due to the excess amount of
surfactant.
Use of co-solvents can destroy the soft gelatin capsule
shells.
53PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
54. FACTORS AFFECTING SMEDDS
1. Dose of drug: The drugs which have low solubility at
high dose are not suitable for SMEDDS. The drugs
required to administer at high dose should possess good
solubility in the components used at least in oil phase.
2. Solubility of drug: The drug should be highly soluble
which influences its bioavailability. The incorporation of
surfactants and co-surfactants at high concentration can
cause risk of precipitation.
54PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
55. 3. Polarity of lipid phase: Release of drug is highly
influenced by polarity of lipid phase. High polarity value
increases the rate of release.
4. Droplet size and charge: Smaller the droplet size and
larger the surface area increases absorption and if the
droplet is positively charged the drugs can penetrate into
the physiological barrier in deep leads to improved
bioavailability
55PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
56. Formulation of SMEDDS
SMEDDS formulation containing following components –
1) Oil phase
2) Primary surfactant
3) Secondary surfactant (co-surfactant)
4) Co-Solvent
These isotropic systems are usually easier to formulate than
ordinary emulsion. The type of associated structure formed from
these components at particular temperature depends not only on
the chemical nature of each component but also on their relative
concentration.
56PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
57. 1) Oil phase :
In order to make SMEDDS systems pharmaceutically
acceptable, it is necessary to prepare such systems by
using nontoxic and safe components.
Oil from natural sources and their derivatives, eg.
triglycerides and fatty acid methyl esters are easily
degraded by microorganism and considered to be
harmless to the environment.
57PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
58. • An acceptable lipophilic phase for pharmaceutical
uses would be vegetable oils.
• The extension of a micro emulsion region generally
depends on nature of oil. This is due to differences in
oil penetration into the surfactant layer.
Eg.- Castor oil, Sunflower oil, Olive oil, Sesame oil,
Hydrogenated specialty oils
58PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
59. 2) Surfactant:
• A surfactant molecule is formed by two parts with
different affinities for the solvents.
• One of them has affinity for water (polar solvents)
and the other has for oil (non-polar solvents).
• A little quantity of surfactant molecules rests upon
the water-air interface and decreases the water surface
tension value (the force per unit area needed to make
available surface).
• That is why the surfactant name: “surface active
agent”. Eg- Lecithin
59PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
60. 3) Co-surfactant:
• Most single-chain surfactants do not lower the oil-
water interfacial tension sufficiently to form micro
emulsions nor are they of the correct molecular
structure.
• Further under certain condition, a combination of oil,
water and surfactant will result in a phase where
there are orderly planes of oil and water separated by
monomolecular layer of surfactant.
60PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
61. • This type of phase is known as liquid crystal
(lamellar phase).
• Liquid crystals formation can be detected by large
increase in viscosity.
• Co-surfactant is added to further lower the interfacial
tension between the oil and water phase, fluidize the
hydrocarbon region of the interfacial-film, and to
influence the film curvature.
61PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
62. 4) Co-solvents:
• The production of an optimum SMEDDS requires
relatively high concentrations (generally more than
30% w/w) of surfactants.
• Organic solvents such as, ethanol, propylene glycol
(PG), and polyethylene glycol (PEG) are suitable
for oral delivery, and they enable the dissolution of
large quantities of either the hydrophilic surfactant or
the drug in the lipid base
62PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
63. 5. Consistency Builder:
Additional material can be added to alter the
consistency of the emulsion; such materials
Include tragacanth, cetyl alcohol, stearic acid and/or
beeswax etc.
6. Polymers
Inert polymer matrix representing from 5 to 40% of
composition relative to the weight,
Which is not ionizable at physiological pH and being
capable of forming matrix are used.
Eg.- Hydroxy propyl methyl cellulose, ethyl cellulose,
etc.
63PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
64. MECHANISM OF SELF-EMULSIFICATION
Self-emulsification occurs when the entropy change
that favors dispersion is greater than the energy
required to increase the surface area of the dispersion.
The free energy of the conventional emulsion is a direct
function of the energy required to create a new surface
between the water and oil phases and can be described
by the equation:
∆G = ∑Nπr2s
64PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
65. • Where ∆G is the free energy associated with the
process (ignoring the free energy of mixing),
• N is the number of droplets of radius r and S
represents the interfacial energy.
• The two phases of emulsion tend to separate with
time to reduce the interfacial area and, subsequently,
the emulsion is stabilized by emulsifying agents,
which form a monolayer of emulsion droplets, and
hence reduces the interfacial energy, as well as
providing a barrier to prevent coalescence.
65PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
66. 1. Spray drying
2. Adsorption of solid carriers
3. Melt extrusion
4. Melt granulation
METHODS OF PREPARATION
66PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
67. Determination of droplet size / distribution and zeta-potential.
Rheological determination
Polarity
Dispersibility test
Cloud point determination
Refractive index
Visual evaluation
Droplet size analysis
Dilution study
EVALUATION OF SMEDDS
67PHARMACEUTICAL DISPERSION, By :Dr. Umesh Kumar Sharma and Shyma
M S
68. 68
By :
Dr. Umesh Kumar Sharma and Shyma M S
Department of Pharmaceutics,
Mar Dioscorus College of Pharmacy,
Alathara, Sreekariyam,
Thiruvananthapuram, Kerala, India
Thank You